Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Masonglory closes US$1,000,500 private placement of 667,000 Class A shares at US$1.50 each

Masonglory closes US$1,000,500 private placement of 667,000 Class A shares at US$1.50 each

BitgetBitget2026/10/06 13:25

Masonglory closed a private placement on Oct. 5, 2026, issuing 667,000 Class A ordinary shares at US$ 1.50. Gross proceeds totaled US$ 1,000,500, before offering expenses. Investors also received Series A warrants for 667,000 shares at US$ 1.30, Series B warrants for 667,000 shares at US$ 1.10. Warrants are exercisable immediately, expire two years from issuance. Securities were sold offshore without Securities Act registration, issued as restricted securities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Masonglory Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-26-004602), on October 06, 2026, and is solely responsible for the information contained therein.

  • Masonglory closed a private placement on Oct. 5, 2026, issuing 667,000 Class A ordinary shares at US$ 1.50.
  • Gross proceeds totaled US$ 1,000,500, before offering expenses.
  • Investors also received Series A warrants for 667,000 shares at US$ 1.30, Series B warrants for 667,000 shares at US$ 1.10.
  • Warrants are exercisable immediately, expire two years from issuance.
  • Securities were sold offshore without Securities Act registration, issued as restricted securities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Masonglory Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-26-004602), on October 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21